New Pancreatic Cancer Pill Doubles Survival Time for Patients

For the first time in decades, pancreatic cancer patients have something their doctors haven't been able to offer before: real hope.

The FDA just approved daraxonrasib, a new pill that helped patients with metastatic pancreatic cancer live nearly twice as long as those receiving standard chemotherapy. In a global trial of 500 patients, those taking the drug survived a median of 13.2 months compared to much shorter times with traditional treatment.

"This is a monumental shift in the treatment of pancreas cancer," said Dr. Peter Hosein, a medical oncologist at the University of Miami's Sylvester Comprehensive Cancer Center. "It's a historic day for pancreatic cancer."

What makes this drug different is how it works. Instead of chemotherapy that attacks cells throughout the body, daraxonrasib targets specific RAS signaling pathways that fuel pancreatic cancer growth. Scientists have tried for years to successfully target RAS, one of the most important drivers of this disease.

The approval was even broader than researchers expected. While the trial required patients to have a specific KRAS mutation, the FDA approved the therapy for all eligible patients with metastatic pancreatic adenocarcinoma regardless of mutation status.

For 80-year-old Julian Itzkowitz of Port St. Lucie, Florida, the impact is deeply personal. After his pancreatic cancer spread to his lungs, chemotherapy made him too sick to continue. Three months ago, he started taking daraxonrasib through an early access program.

"My appetite is good. I feel good about myself, and I can travel without any problems," he said. A recent scan showed his tumors had shrunk since starting treatment.

His mother died of pancreatic cancer 20 years ago, when patients had far fewer options. "I hope I can stay on this drug for a long time," he said.

The Ripple Effect

This breakthrough reaches beyond individual patients. Sylvester Comprehensive Cancer Center was the only South Florida site to participate in the pivotal trial and became the first Florida site to offer expanded access before FDA approval.

Researchers there are already studying what comes next. They're investigating why some tumors develop resistance and whether the drug might help prevent cancer from returning after surgery.

Dr. Hosein noted that patients on the drug during trials experienced something crucial beyond survival numbers. "Despite having some side effects, their quality of life was better because their cancer was better controlled," he said. "And the thing that has the biggest impact on quality of life is cancer control."

The approval gives doctors more than a new prescription option when patients walk in with devastating news. "A lot of times when people come in with a new diagnosis of pancreas cancer, they are depressed and their whole world is turned upside down," Dr. Hosein said.

Now they can offer something that wasn't available before: a treatment that works differently, lasts longer, and opens doors that used to be closed.